When was DISCO Pharmaceuticals founded?

DISCO Pharmaceuticals was founded in 2022 and raised its 1st funding round 2 years after it was founded.

Where is DISCO Pharmaceuticals located?

DISCO Pharmaceuticals is headquartered in Cologne, Germany.

Who is the current CEO of DISCO Pharmaceuticals?

Roman Thomas of DISCO Pharmaceuticals. They have also founded 1 company.

How many employees does DISCO Pharmaceuticals have?

As of Sep 30, 2026, the latest employee count at DISCO Pharmaceuticals is 37.

Is DISCO Pharmaceuticals a funded company?

DISCO Pharmaceuticals is a funded company, having raised a total of $63.8M across 2 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Jan 16, 2024.

When was the latest funding round of DISCO Pharmaceuticals?

DISCO Pharmaceuticals' latest funding was a $***** Seed round on Dec 11, 2025, with participation from 6 investors. Its primary sector is Oncology. In Germany, the Oncology sector has seen $78.5M in funding in 2026 to date.

Where does DISCO Pharmaceuticals rank among its competitors?

DISCO Pharmaceuticals ranks 353rd amongst 3423 active competitors, of which 1128 are funded. It stands 9th in terms of total funding among its competitors. The most recent competitor to raise funding was Immuneel, which secured $10.5M in Jun, 2026.

Who are the top competitors of DISCO Pharmaceuticals?

DISCO Pharmaceuticals' top competitors include Jazz Pharmaceuticals, BeiGene and Kite Pharma. Among them, Immuneel secured the most recent funding round in June, 2026.

DISCO Pharmaceuticals - 2026 Company Profile, Team, Funding & Competitors

DISCO Pharmaceuticals is a seed company based in Cologne (Germany), founded in 2022 by Roman Thomas. It operates as a Developer of target-directed therapeutic modalities for the treatment of cancer. DISCO Pharmaceuticals has raised $63.8M in funding from investors like Ackermans & van Haaren, NRW.Bank and Sofinnova Partners. The company has 3423 active competitors, including 1128 funded and 788 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, BeiGene and Kite Pharma.

Company Details

Developer of target-directed therapeutic modalities for the treatment of cancer. The company specializes in mapping the surfaceome of cancer cells and develop first-in-class cancer drugs. It identifies proteins and protein communities across the entire cancer cell surface addressing the need for target candidates for both mono- and bi-specific antibodies.

Website: discopharma.de
Email ID: *****@discopharma.de
Phone Number: +49 **********

Key Metrics

Founded Year

2022

Location

Cologne, Germany

Stage

Seed

Total Funding

$63.8M in 2 rounds

Latest Funding Round

Seed, Dec 11, 2025, $*****

Investors

Ackermans & van Haaren & 5 more

Ranked

353^rd among 3423 active competitors

Employee Count

37 as on Sep 30, 2026

Similar Companies

BeiGene & 587 more

View DISCO Pharmaceuticals' full profile

DISCO Pharmaceuticals is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Reports
DISCO Pharmaceuticals GmbH CIN: HRB110121 , Germany, Active	Mar 29, 2022	-	-

DISCO Pharmaceuticals has raised a total funding of $63.8M over 2 rounds. Its first funding round was on Jan 16, 2024. Its latest funding round was a Seed round on Dec 11, 2025 for $*****. 6 investors participated in its latest round. DISCO Pharmaceuticals has 6 institutional investors.

Here is the list of recent funding rounds of DISCO Pharmaceuticals:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Dec 11, 2025	6593184	Seed	8527513	6191244	6960556	3895214
Jan 16, 2024	5182591	Seed	3783861	3120132	Sofinnova Partners	Panakes Partners & 2 more

Access funding benchmarks and valuations. Sign up today!

View details of DISCO Pharmaceuticals's funding rounds and investors

The founders of DISCO Pharmaceuticals is Roman Thomas. Roman Thomas is the CEO of DISCO Pharmaceuticals.

Here are the details of DISCO Pharmaceuticals' key team members:

Roman Thomas: Co-Founder & CEO of DISCO Pharmaceuticals.

View details of DISCO Pharmaceuticals's Founder profiles and Board Members

DISCO Pharmaceuticals' employee count trend

DISCO Pharmaceuticals has 37 employees as of Sep 26. Here is DISCO Pharmaceuticals's employee count trend over the years:

Employee count trend for DISCO Pharmaceuticals

Uncover DISCO Pharmaceuticals' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of DISCO Pharmaceuticals include Jazz Pharmaceuticals, BeiGene and Kite Pharma. Here is the list of Top 10 competitors of DISCO Pharmaceuticals, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, T. Rowe Price & 13 others	77/100
3rd	Kite Pharma 2009, Los Angeles (United States), Acquired	Developer of cancer immunotherapy products using genetic engineering	$97.7M	Alta Partners, Amgen Business Development ... & 10 others	76/100
4th	Attovia 2023, Fremont (United States), Public	Developer of antibody-based therapeutics for immune-mediated diseases and oncology	$255M	Deep Track Capital, Goldman Sachs Asset Management ... & 13 others	72/100
5th	Tango Therapeutics 2017, Cambridge (United States), Public	Developer of drugs for the treatment of cancer	$165M	Boxer Capital, Casdin Capital & 8 others	72/100
6th	Elicio 2012, Cambridge (United States), Public	Developer of vaccines for treating cancer	$47.4M	Dreavent, Efung Capital & 5 others	72/100
7th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 22 others	71/100
8th	BioNTech 2008, Mainz (Germany), Public	Developer of immunotherapeutics for the treatment of cancer and other diseases	$861M	Fidelity Investments, Redmile Group & 28 others	71/100
9th	Erasca 2018, San Diego (United States), Public	Developer of small molecule based therapeutics for cancer	$300M	Cormorant Asset Management, Arch Venture Partners ... & 13 others	71/100
10th	Strand Therapeutics 2017, Cambridge (United States), Series B	Provider of platform to deliver mRNA therapeutics for multi functional treatments	$256M	Kinnevik, Playground Global & 19 others	71/100
353rd	DISCO Pharmaceuticals 2022, Cologne (Germany), Seed	Developer of target-directed therapeutic modalities for the treatment of cancer	$63.8M	AbbVie, Sofinnova Partners & 4 others	55/100

Get insights and benchmarks for competitors of 2M+ companies! Sign up today!

Looking for more details on DISCO Pharmaceuticals's competitors? Click here to see the top ones

DISCO Pharmaceuticals has made no investments or acquisitions yet.

Here is the latest report on DISCO Pharmaceuticals's sector:

Free

Oncology - Sector Report

Edition: September, 2026 (75 Pages)

View all reports related to DISCO Pharmaceuticals

Media has covered DISCO Pharmaceuticals for a total of 5 events in the last 1 year, 2 of them have been about company updates and 1 about partnerships.